SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Jul 22, 2016
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: July 22, 2016 · CIK: 0001607678 · Accession: 0001564590-16-021354
AI Filing Summary & Sentiment
File numbers found in text: 333-212134
Letter
vktx-corresp_20160722.htm
12340 El Camino Real, Suite 250
San Diego, CA 92130
July 22, 2016
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance
Mary Beth Breslin
Christina Thomas
Re:
Viking Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-212134
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-212134) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on July 26, 2016 or as soon thereafter as may be practicable. As of the date above, there is no managing or principal underwriter for any of the Company’s securities that may be offered pursuant to the Registration Statement. Future managing or principal underwriters, if any, will be identified in a prospectus supplement to the Registration Statement at the time of offering.
The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. The Registrant hereby acknowledges that:
·
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Paul Hastings LLP, by calling Jeffrey T. Hartlin at (650) 320-1804. The Company hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Mr. Hartlin via email to jeffhartlin@paulhastings.com or facsimile to (650) 320-1904 and via mail c/o Paul Hastings LLP, 1117 S. California Avenue, Palo Alto, CA 94304.
Sincerely,
VIKING THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm vktx-corresp_20160722.htm 12340 El Camino Real, Suite 250 San Diego, CA 92130 July 22, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance Mary Beth Breslin Christina Thomas Re: Viking Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-212134 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-212134) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on July 26, 2016 or as soon thereafter as may be practicable. As of the date above, there is no managing or principal underwriter for any of the Company’s securities that may be offered pursuant to the Registration Statement. Future managing or principal underwriters, if any, will be identified in a prospectus supplement to the Registration Statement at the time of offering. The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. The Registrant hereby acknowledges that: · should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Paul Hastings LLP, by calling Jeffrey T. Hartlin at (650) 320-1804. The Company hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration. Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Mr. Hartlin via email to jeffhartlin@paulhastings.com or facsimile to (650) 320-1904 and via mail c/o Paul Hastings LLP, 1117 S. California Avenue, Palo Alto, CA 94304. Sincerely, VIKING THERAPEUTICS, INC. By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer cc:Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)